Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy

BMC Surgery

Table 1 Demographic table of study collective and correlation analysis between relapse compartment and clinicopathological variables from primary PDAC; n = 141

	No metastases n = 54	Hepatic, n = 43	Pulmonary, n = 17	Local, n = 28	*p-value*
Age in years
Median (range)	68 (17–95)	69 (46–86)	64 (41–81)	63.5 (42–88)	0.521
Gender					0.109
Female	27	19	8	11
Male	27	24	9	17
Tumor localisation					0.265
Pancreatic head	45	42	16	25
Pancreatic tail	9	1	1	3
T-stage					0.478
T1	8	2	1	2
T2	26	27	9	20
T3	20	13	7	5
T4	0	1	0	1
N-stage					0.157
N0	17	6	3	6
N1	33	31	14	22
N2	4	6	0	0
Grading					0.446
G1/G2	33	25	8	19
G3	21	18	9	9
Pn					0.483
Pn0	15	7	5	5
Pn1	36	33	12	20
Missing	3	3	0	3
L					0.161
L0	34	20	6	14
L1	17	20	11	11
Missing	3	3	0	3
V					0.011
V0	41	23	15	22
V1	10	17	2	3
Missing	3	3	0	3
Resection status					0.305
R0CRM−	49	39	14	21
R1/R0CRM +	5	4	3	7
Chemotherapy					0.692
MD regime	14	8	3	7
FOLFIRINOX	3	6	1	1
Gemcitabine mono	30	29	9	15
No CTx	7	0	4	5

Only venous invasion correlated with metachronous hepatic metastases. Pearson Test and Mann–Whitney U test were used to test for statistical significance. p-value ≤ 0.05 indicates significance
CTx chemotherapy, MD multidrug, Pn perineural invasion, L: lymphatic invasio, V venous invasion

ISSN: 1471-2482